Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
28 nov. 2018 08h00 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
21 nov. 2018 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
19 nov. 2018 08h00 HE
|
Minerva Neurosciences, Inc
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe...
Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018
15 nov. 2018 08h30 HE
|
Minerva Neurosciences, Inc
Minerva management to provide update on Phase 3 clinical trial with roluperidone and single-dose escalation study findings Additional topics to include review of recent BDNF data with roluperidone...
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
07 nov. 2018 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates
05 nov. 2018 07h30 HE
|
Minerva Neurosciences, Inc
Data readouts from five ongoing late-stage trials expected in 2019 WALTHAM, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical...
Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018
29 oct. 2018 08h30 HE
|
Minerva Neurosciences, Inc
Management to host conference call WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the...
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF)
22 août 2018 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates
02 août 2018 07h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018
26 juil. 2018 08h30 HE
|
Minerva Neurosciences, Inc
WALTHAM, Mass., July 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...